Salemonline Journal

Liver Cancer Pipeline Analysis: 75+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Liver Cancer Pipeline Analysis: 75+ Companies are Working to Improve the Treatment Space | DelveInsight

November 08
21:28 2022
Liver Cancer Pipeline Analysis: 75+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Liver Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Liver Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Liver Cancer Pipeline Report

  • DelveInsight’s Liver Cancer Pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Liver Cancer.
  • The leading Liver Cancer Companies such as Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, , Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others are evaluating novel liver cancer drugs candidate to improve the treatment landscape.
  • Promising liver cancer pipeline therapies in various stages of development include Tiragolumab, VG161,  IM83, MTL-CEBPA, IBR900, Talimogene Laherparepvec, SHR-1210, ABSK-011, MIV-818, TSR-022, Tirapazamine, GNS561,  ET140203, Q702, Relatlimab, LioCyx-M,  DKN-01, SD-101,  BO-112, RO7119929,  PV-10, PF-07263689, E7386,  GEN2, TTI-101, MRG002, TAK-500, TAEK-VAC-HerBy, INT230-6, ARB202, QBS10072S, A166, NBTXR3, TBI-1301, CVM-1118, Namodenoson, STP705,  BLU-554, SRF388, YIV-906, Tivozanib, KN046, DNAJB1-PRKACA, PTX-9908, SHR-8068, T-ACE Oil, SynOV1.1, SCT-I10A, ABX196, GT90001, ABSK-011, ADI-PEG20,  HLX07, VG161, Vax NK/HCC, ERY974, Ociperlimab, HX008, CS1003, ATG-008, Icaritin, P1101, CT0181, LCAR-H93T Cells, and others.
  • In February 2021, the U.S. Food & Drug Administration (FDA) granted Kintor Pharma an investigational new drug (“”IND””) application for ALK-1 antibody as a second-line treatment for HCC.
  • In the Liver Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liver Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Request a sample and discover the recent advances in Liver Cancer treatment @ Liver Cancer Pipeline Report

 

Liver Cancer Overview

Liver cancer is a cancer that originates in the liver, and is an aggressive tumor that frequently occurs in the setting of chronic liver disease and cirrhosis. Primary liver cancer, or hepatocellular carcinoma (HCC), is the fifth most common cancer in males and the seventh most common cancer in females, and is the third leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC), the primary cancer of the liver, is derived from hepatocytes and occurs in more than approximately 80% of cases of liver cancer. The HCC carcinogenesis is often associated with liver cirrhosis resultant from chronic liver diseases as chronic hepatitis, HBV or HCV infection, and autoimmune hepatitis. Other risk factors include excessive alcohol consumption, NASH, non-alcoholic fatty liver disease (NAFLD), exposure and ingestion of aflatoxin, diabetes mellitus, tobacco, and sporadically genetic diseases such as alpha-1 antitrypsin deficiency, hemochromatosis, tyrosinemia, porphyria and Wilson’s disease.

 

Recent Breakthroughs of Liver Cancer Treatment Landscape

  • In June 2022, Teclison announced the peer-reviewed publication of a study demonstrating the safety, tolerability, and preliminary efficacy of its trans-arterial tirapazamine chemoembolization (TATE) therapy in patients with unresectable early- and intermediate-stage hepatocellular carcinoma (HCC), also known as liver cancer.Tirapazamine (TPZ) with conventional trans-arterial chemoembolization had a good safety profile and promising efficacy signals in early- and intermediate-stage liver cancer, including in patients who had progression or recurrence after standard therapy.
  • In May 2022SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC, and HCC. Confirmed partial responses (PR) were observed in two patients who received SRF388 monotherapy treatment: one in non-small-cell lung cancer (NSCLC) (previously reported) and one in clear cell renal cell carcinoma (RCC). In addition, a PR was observed in a patient who was treated with SRF388 in combination with pembrolizumab for hepatocellular carcinoma (HCC).
  • In May 2022, Kintor Pharmaceutical Limited announced the first patient dosing in the United States of its multi-regional phase II clinical trial (NCT05178043) of ALK-1 antibody (GT90001) and Nivolumab (Opdivo) combination therapy for the treatment of advanced Hepatocellular Carcinoma (HCC).
  • In April 2022, Tvardi Therapeutics, Inc. announced that its lead product, TTI-101, had been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC).
  • In January 2022, MiNA Therapeutics Limited announced that it has dosed the first patient in a global Phase 2 clinical trial (OUTREACH-2) of MTL-CEBPA in combination with second line standard of care sorafenib (a tyrosine kinase inhibitor (TKI)) in advanced hepatocellular carcinoma (HCC or liver cancer).
  • In January 2022, Abivax SA announced the detailed results of the dose escalation phase of its clinical phase 1/2 study conducted with ABX196 to treat hepatocellular carcinoma (HCC). In this study, heavily pre-treated hepatocellular cancer (HCC) patients were administered ABX196 in combination with checkpoint inhibitor nivolumab, including patients who were previously exposed to checkpoint inhibitor treatments. These results support the further clinical development of ABX196 in the HCC setting.
  • In December 2021, Medivir AB announced that the first patient with hepatocellular carcinoma (HCC) had been dosed with MIV-818 in a phase 1b/2a combination study with the company’s candidate drug MIV-818. In the study, MIV-818 will be given in combination with two other medicines, either with Lenvima®, a tyrosine kinase inhibitor or with Keytruda®, an anti-PD-1 checkpoint inhibitor. Lenvima® and Keytruda®, respectively, are currently approved as monotherapy treatments for HCC.
  • In November 2021, Eureka Therapeutics, Inc., announced the initiation of ARYA-2, a Phase I/II open-label, dose-escalation clinical trial of ET140203 ARTEMIS® T-cell therapy in pediatric patients with relapsed or refractory hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS), or hepatocellular carcinoma (HCC).

 

Find out more about Liver Cancer Medication @ Liver Cancer Treatment

 

Liver Cancer Emerging Drugs

  • SRF388: Surface Oncology
  • MTL-CEBPA: MiNA Therapeutics
  • APX3330: Ocuphire Pharma
  • Fostroxacitabine bralpamide: Medivir
  • CDX-527: Celldex Therapeutics

 

DelveInsight’s Liver Cancer Pipeline Report covers around 75+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Learn more about the novel and emerging Liver Cancer pipeline therapies @ Liver Cancer Clinical Trials

 

Scope of the Liver Cancer Pipeline Report

  • Coverage- Global
  • Liver Cancer Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Liver Cancer Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Liver Cancer Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous
  • Liver Cancer Therapeutics Assessment By Molecule Type: Monoclonal antibodies, Peptides, Polymer, Small molecule, Immunotherapy
  • Liver Cancer Therapeutics Assessment By Mechanism of Action: RNA interference, Angiogenesis inhibitors, APEX1 protein inhibitors, DNA apurinic apyrimidinic site lyase inhibitors, DNA synthesis inhibitors, Arginine deiminase replacements, Type 1 fibroblast growth factor receptor antagonists, Vascular endothelial growth factor receptor-2 antagonists, Type 4 fibroblast growth factor receptor antagonists
  • Liver Cancer Companies- Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, , Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others
  • Liver Cancer Therapies- Tiragolumab, VG161,  IM83, MTL-CEBPA, IBR900, Talimogene Laherparepvec, SHR-1210, ABSK-011, MIV-818, TSR-022, Tirapazamine, GNS561,  ET140203, Q702, Relatlimab, LioCyx-M,  DKN-01, SD-101,  BO-112, RO7119929,  PV-10, PF-07263689, E7386,  GEN2, TTI-101, MRG002, TAK-500, TAEK-VAC-HerBy, INT230-6, ARB202, QBS10072S, A166, NBTXR3, TBI-1301, CVM-1118, Namodenoson, STP705,  BLU-554, SRF388, YIV-906, Tivozanib, KN046, DNAJB1-PRKACA, PTX-9908, SHR-8068, T-ACE Oil, SynOV1.1, SCT-I10A, ABX196, GT90001, ABSK-011, ADI-PEG20,  HLX07, VG161, Vax NK/HCC, ERY974, Ociperlimab, HX008, CS1003, ATG-008, Icaritin, P1101, CT0181, LCAR-H93T Cells, and others.

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Liver Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Liver Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. ADI-PEG20: Polaris Group
  9. Mid Stage Products (Phase II)

10. Brivanib alaninate: ZAI Lab

11. Early Stage Products (Phase I)

12. ABSK 011: Abbisko Therapeutics

13. Preclinical and Discovery Stage Products

14. Drug name: Company name

15. Inactive Products

16. Liver Cancer Key Companies

17. Liver Cancer Key Products

18. Liver Cancer- Unmet Needs

19. Liver Cancer- Market Drivers and Barriers

20. Liver Cancer- Future Perspectives and Conclusion

21. Liver Cancer Analyst Views

22. Liver Cancer Key Companies

23. Appendix

 

Dive deep into rich insights for drugs for Liver Cancer Treatment, visit @ New Drug for Liver Cancer Treatment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles